» Articles » PMID: 32665858

D-dimer As a Biomarker for Disease Severity and Mortality in COVID-19 Patients: a Case Control Study

Overview
Publisher Biomed Central
Specialty Critical Care
Date 2020 Jul 16
PMID 32665858
Citations 284
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Over 5,488,000 cases of coronavirus disease-19 (COVID-19) have been reported since December 2019. We aim to explore risk factors associated with mortality in COVID-19 patients and assess the use of D-dimer as a biomarker for disease severity and clinical outcome.

Methods: We retrospectively analyzed the clinical, laboratory, and radiological characteristics of 248 consecutive cases of COVID-19 in Renmin Hospital of Wuhan University, Wuhan, China from January 28 to March 08, 2020. Univariable and multivariable logistic regression methods were used to explore risk factors associated with in-hospital mortality. Correlations of D-dimer upon admission with disease severity and in-hospital mortality were analyzed. Receiver operating characteristic curve was used to determine the optimal cutoff level for D-dimer that discriminated those survivors versus non-survivors during hospitalization.

Results: Multivariable regression that showed D-dimer > 2.0 mg/L at admission was the only variable associated with increased odds of mortality [OR 10.17 (95% CI 1.10-94.38), = 0.041]. D-dimer elevation (≥ 0.50 mg/L) was seen in 74.6% (185/248) of the patients. Pulmonary embolism and deep vein thrombosis were ruled out in patients with high probability of thrombosis. D-dimer levels significantly increased with increasing severity of COVID-19 as determined by clinical staging (Kendall's tau-b = 0.374, = 0.000) and chest CT staging (Kendall's tau-b = 0.378, = 0.000). In-hospital mortality rate was 6.9%. Median D-dimer level in non-survivors ( = 17) was significantly higher than in survivors ( = 231) [6.21 (3.79-16.01) mg/L versus 1.02 (0.47-2.66) mg/L, = 0.000]. D-dimer level of > 2.14 mg/L predicted in-hospital mortality with a sensitivity of 88.2% and specificity of 71.3% (AUC 0.85; 95% CI = 0.77-0.92).

Conclusions: D-dimer is commonly elevated in patients with COVID-19. D-dimer levels correlate with disease severity and are a reliable prognostic marker for in-hospital mortality in patients admitted for COVID-19.

Citing Articles

Role of peak D-dimer in predicting mortality and venous thromboembolism in COVID-19 patients.

Lee R, Wang S, Akerman M, Joseph D Sci Prog. 2025; 108(1):368504241247982.

PMID: 40012497 PMC: 11866355. DOI: 10.1177/00368504241247982.


The Association Between Diabetes and the Outcome of COVID-19 Infection in Bethlehem, Palestine: A Case-Control Study.

Abu-Helu R, Zeer M, Adwan G J Pathog. 2025; 2024:1051658.

PMID: 39995847 PMC: 11850064. DOI: 10.1155/2024/1051658.


Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.

Fekete M, Lehoczki A, Szappanos A, Toth A, Mahdi M, Sotonyi P Geroscience. 2025; 47(1):745-779.

PMID: 39777702 PMC: 11872997. DOI: 10.1007/s11357-024-01487-4.


Serial biomarker measurements may be helpful to predict the successful application of high flow nasal cannula in COVID-19 pneumonia patients.

Ikeda R, Pham A, Zhang G, Lai J, Davis J, Devendra G Sci Rep. 2025; 15(1):756.

PMID: 39755869 PMC: 11700188. DOI: 10.1038/s41598-025-85210-z.


Efficient clinical decision-making process via AI-based multimodal data fusion: A COVID-19 case study.

Moris D, de Moura J, Marcos P, Miguez Rey E, Novo J, Ortega M Heliyon. 2024; 10(20):e38642.

PMID: 39640748 PMC: 11619951. DOI: 10.1016/j.heliyon.2024.e38642.


References
1.
Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg B, Levin M . Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(1):122-124. PMC: 7202841. DOI: 10.1016/j.jacc.2020.05.001. View

2.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

3.
Wells P, Anderson D, Rodger M, Ginsberg J, Kearon C, Gent M . Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000; 83(3):416-20. View

4.
Dai R, Kong Q, Mao B, Xu W, Tao R, Wang X . The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulm Med. 2018; 18(1):12. PMC: 5778745. DOI: 10.1186/s12890-018-0587-7. View

5.
Gralinski L, Baric R . Molecular pathology of emerging coronavirus infections. J Pathol. 2014; 235(2):185-95. PMC: 4267971. DOI: 10.1002/path.4454. View